Anixa Biosciences 2025 Q3 Earnings 31.2% Net Loss Reduction

Anixa Biosciences reported its fiscal 2025 Q3 earnings on Sep 10th, 2025. The company demonstrated progress in narrowing losses, despite maintaining zero revenue. The stock has shown limited movement in the short term.

Anixa Biosciences reported total revenue of $0 for the third quarter of 2025, reflecting no change from the $0 recorded in the same period of the previous year. The company continues to operate without revenue-generating activities during this reporting period.

Anixa Biosciences improved its earnings performance in the third quarter of 2025, reducing its net loss to $-2.28 million from $-3.31 million in the same period of the previous year, representing a 31.2% decrease. On a per-share basis, the company narrowed its loss to $0.07 from $0.10, indicating a 30.0% improvement. The company’s ability to reduce its net loss reflects ongoing cost management and operational efficiency.

The stock price of Anixa Biosciences remained flat by 0.00% during the latest trading day but showed a modest increase of 1.00% during the most recent full trading week. Month-to-date, the stock has advanced by 1.34%, showing slight positive momentum in the early post-earnings period.

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, expressed optimism about the preliminary data from the Phase 1 breast cancer vaccine trial, noting that the vaccine is well tolerated and has generated immune responses in over 70% of patients. He emphasized these findings as a foundation for planning Phase 2 trials, including discussions with the FDA, protocol development, and manufacturing. Kumar highlighted the innovative nature of the vaccine’s target and its potential to address a major unmet need in the breast cancer market, especially for triple-negative and genetically high-risk populations. He conveyed a confident outlook, framing the vaccine as a potential new paradigm in immuno-oncology.

Anixa Biosciences expects to submit the final study report to the Department of Defense by August 2025 and prepare a Clinical Study Report for submission to the FDA. The company plans to present all trial data at a major upcoming scientific meeting and will transfer the Investigational New Drug application from Cleveland Clinic to Anixa as development continues.

Additional News

In the week leading up to Anixa’s earnings report, several key developments in the business and political landscape of Nigeria drew attention. On September 9, 2025, the UK lifted a travel ban on Kaduna state and upgraded its travel advisory to 'amber,' signaling a reduction in travel risks. In another major development, Larry Ellison was reported to have overtaken Elon Musk as the world’s richest man, a milestone that highlighted the shifting tides in global tech and finance.

Political discussions also intensified as Nigeria’s African Democratic Congress (ADC) urged the public not to judge the party based on its performance in recent by-elections. Meanwhile, the Federal Government made headlines for collecting N600 billion in VAT from international companies, including Facebook, underscoring efforts to boost domestic revenue.

On the international stage, Oracle shares surged over 35% following major AI deal announcements, indicating strong investor confidence in the company’s strategic direction. Additionally, Nigeria’s political landscape saw increasing calls for early campaign regulation, with the police and INEC reportedly taking steps to prevent premature political activities. These developments reflect the dynamic and multifaceted nature of the Nigerian and global financial and political environment in the first week of September 2025.